WebConsolidation was cladribine (5 mg/m 2) and cytarabine (1 g/m 2 for patients aged <60 years and 0·75 g/m 2 for patients aged ≥60 years) on days 1-3 and idarubicin (8 mg/m 2) on days 1-2. Venetoclax (400 mg) was given on days 2-8 with each course. Patients with a known FLT3-ITD or FLT3-TKD mutation received midostaurin or gilteritinib. WebAug 20, 2011 · Purpose: To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia. Patients and methods: Twelve patients with acute leukemia (11 with acute myeloid leukemia [AML]) received sorafenib on days 1 to 7 and …
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and
WebJun 5, 2016 · Simultaneous determination of clofarabine and cytarabine in human plasma by LC-MS/MS Combination of cytostatic agents is a basic principle in the treatment of cancer. For the treatment of acute myeloid leukemia (AML), purine analogs, like clofarabine and cytarabine act synergistically. Little is known, however, on their … WebNov 16, 2012 · Clofarabine is a second generation nucleoside analogue with multiple mechanisms of action including inhibition of ribonucleotide reductase, suppression of … robo advisor vs wealth manager
Histiocytic sarcoma: secondary neoplasm or “transdifferentiation” in ...
WebOct 1, 2003 · Both clofarabine and cytarabine are active in adult acute leukemia, and target 2 different DNA sites. 38 The pharmacokinetic profile of clofarabine is favorable compared with other deoxyadenosine analogs, and in the preclinical settings, pretreatment with clofarabine increases the ability of cells to accumulate ara-cellular triphosphate … WebAug 18, 2015 · A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic ... WebPhase 2 studies of clofarabine plus low-dose cytarabine (CLDA) as frontline therapy for elderly AML patients demonstrated high response and acceptable toxicity. Patients and methods: We hypothesized that induction therapy with CLDA provides equivalent outcomes to but is less toxic than intensive induction in these patients. robo advisor vs traditional